Oppenheimer Maintains Outperform Rating and $75 PT on Chemed Corporation

A report from Oppenheimer reiterates its Outperform rating and $75 price target on Chemed Corporation CHE. The report states, “CHE reported 3Q11 adjusted EPS of $1.20 (GAAP $1.04) compared to our estimate of $1.14. As a note, our estimate is consistent with the company's adjusted earnings, which exclude one-time costs ($0.03), interest expense ($0.06) and stock option expenses ($0.07)." CHE closed yesterday at $53.31.